New Version of Cardiac SPECT System Debuts in U.S.

Siemens Healthineers has introduced a new version of its dedicated cardiac nuclear medicine system to the U.S. market. This single-photon emission computed tomography (SPECT) scanner with a reclining patient chair offers nuclear cardiology providers a low total...

Physicians Highlight Potential of Radiopharmaceuticals in Oncology

The Medical Imaging & Technology Alliance (MITA), along with the Council on Radionuclides and Radiopharmaceuticals, Inc. (CORAR) and the Society of Nuclear Medicine & Molecular Imaging (SNMMI), hosted a virtual briefing for Capitol Hill staff this month with...

Nanox Signs Agreement to Deploy 630 Units in Mexico

NANO-X IMAGING LTD, an innovative medical imaging technology company, announced that it has entered into an exclusive distribution agreement with SPI Medical (SPI) for the deployment and introduction of Nanox’s medical imaging services in Mexico. SPI Medical, S. A. P....

Inaugural ICE Webinar Delivers ‘Pertinent’ Information

The Imaging Community Exchange (ICE) magazine continues to grow and part of the growth is a brand-new webinar series where imaging leaders can earn valuable continuing education (CE) credits. The webinar series, dubbed “A cool series for hot topics,” began Tuesday...

Studies Reveal High Performance of Lunit AI in Breast Cancer Detection

Recent studies have shown that Lunit’s AI solution is as accurate as average radiologists when it comes to identifying breast cancer and it could potentially have a role as independent reader in the future, to reduce radiologist workload and possibly to increase cancer detection.

A pair of studies conducted by Dr. Fredrik Strand from Karolinska Institutet and his research team have been recently published in JAMA Oncology and The Lancet Digital Health, well-known to be among the leading peer-reviewed journals in medicine, featuring performance results of Lunit INSIGHT MMG, a commercial AI solution for breast cancer detection from mammograms.

According to the study published in JAMA Oncology, the team conducted the first independent comparison of several commercialized AI. Three different AI algorithms were analyzed including Lunit’s solution (Lunit INSIGHT MMG) to identify breast cancer. They were evaluated in a large retrospective screening cohort.

The graph shows the highest performance of Algorithm 1(Lunit). The wider area of the graph corresponds to the higher performance in Al algorithm.

Based on 8,805 cases, Lunit’s algorithm showed the best accuracy among others, showing around 15 percentage points higher sensitivity than the other two algorithms. It also surpassed the sensitivity of the first-reader radiologists, and achieved a synergistic sensitivity of 88.6% when combining first-readers and Lunit’s AI solution.

“The significant leap in performance comes from our proprietary algorithm, meticulously trained by an unprecedented quantity of data with accurate ground truth,” said Ki Hwan Kim, Chief Medical Officer of Lunit. “Our training dataset includes 72,000 biopsy-proven breast cancer cases, which is considerably more than other algorithms mentioned in the study.”

In line with the high performance, the possibility for AI to triage certain screening examinations was suggested in the study published in The Lancet Digital Health. It focused on how AI-based scoring can be used to reallocate radiologist time from clearly negative mammograms to cases requiring additional attention by radiologists, ultimately reducing their workload and improving cancer detection.

The study proved that for the majority of mammograms receiving a low abnormality score Lunit AI rarely missed any cancers when assessing the data alone, with no radiologists involved. If no radiologist resources were used for 60% of women with the lowest AI scores and were invested into doing MRI for the top 2% AI scores (that were negative after radiologist double reading of the mammograms), a net of 103 of 547 cancers would potentially have been detected up to 2 years earlier, corresponding to a detection rate of 68 cancers per 1000 supplemental screening examinations.

Lunit INSIGHT MMG, AI solution for breast cancer detection from mammograms

Fredrik Strand, a researcher at the Department of Oncology-Pathology at Karolinska Institutet and a radiologist at Karolinska University Hospital explained, “The studies show the potential of commercial AI algorithms as independent readers in screening mammography assessment on a clinically relevant level. The next step for us is to explore how well the Lunit AI algorithm works as an independent reader in a prospective clinical setting. In the future, I am convinced that AI image analysis will contribute to further improvements in overall survival for breast cancer patients.”

“As breast cancer is the second leading cause of death in women, early detection is the best defense in treating the disease,” says Brandon Suh, CEO of Lunit. “It is very meaningful for our algorithm’s high-performance level to be recognized in these well-designed studies based on a significant actual screening cohort data, and we hope to continuously provide the best solution for the right diagnosis of patients.”



Submit a Comment

Your email address will not be published. Required fields are marked *